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Abstract: Our understanding on human neurodegenerative disease was previously limited to
clinical data and inferences about the underlying pathology based on histopathological
examination. Animal models and in vitro experiments have provided evidence for a
cell-autonomous and a non-cell autonomous mechanism for the accumulation of
neuropathology. Combining modern neuroimaging tools to identify distinct neural
networks (Connectomics) with target-specific Positron Emission Tomography (PET)
tracers is an emerging and vibrant field of research with the potential to examine the
contributions of cell-autonomous and non-cell autonomous mechanisms to the spread
of pathology. The evidence provided here suggests that both cell- autonomous and
non-cell autonomous processes relate to the observed in vivo characteristics of protein
pathology and neurodegeneration across the disease spectrum. We propose a
synergistic model of cell- autonomous and non-cell autonomous accounts that
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integrates the most critical factors (i.e., protein strain, susceptible cell feature and
connectome) contributing to the development of neuronal dysfunction and in turn
produces the observed clinical phenotypes. We believe that a timely and longitudinal
pursuit of such research programs will greatly advance our understanding of the
complex mechanisms driving human neurodegenerative diseases.
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Abstract 
 Our understanding on human neurodegenerative disease was previously limited to clinical data 
and inferences about the underlying pathology based on histopathological examination. Animal models 
and in vitro experiments have provided evidence for a cell-autonomous and a non-cell autonomous 
mechanism for the accumulation of neuropathology. Combining modern neuroimaging tools to identify 
distinct neural networks (Connectomics) with target-specific Positron Emission Tomography (PET) 
tracers is an emerging and vibrant field of research with the potential to examine the contributions of 
cell-autonomous and non-cell autonomous mechanisms to the spread of pathology. The evidence 
provided here suggests that both cell- autonomous and non-cell autonomous processes relate to the 
observed in vivo characteristics of protein pathology and neurodegeneration across the disease 
spectrum. We propose a synergistic model of cell- autonomous and non-cell autonomous accounts that 
integrates the most critical factors (i.e., protein strain, susceptible cell feature and connectome) 
contributing to the development of neuronal dysfunction and in turn produces the observed clinical 
phenotypes. We believe that a timely and longitudinal pursuit of such research programs will greatly 







































































Human neurodegenerative diseases are characterized by inclusions of protein aggregates 
comprising amyloid-β (Aβ), Tau, TDP-43 or alpha-synuclein [s 1,s 2,s 3]. A small percentage are caused 
by genetic mutations affecting these proteins or their cellular processing pathways, that results in the 
overproduction, misfolding, aggregation or reduced clearance of the pathologic proteins [s4,s5]. 
Although distinct clinical phenotypes relate to different types of protein aggregates [6,s7], the 
spectrum of neurodegenerative disease shares striking commonalities. The most common risk factor for 
the development is advanced age, suggesting that the biological process of aging by itself contributes 
considerably to pathological neurodegeneration [s8]. Further, the molecular principles of abnormal 
protein aggregation and clearance appear to be similar across different types of brain cells, irrespective 
of the disease type. Third, pathological protein aggregation is not evenly distributed across all brain 
regions, but each type of protein aggregate appears to be initiated in a specific location and to proceed 
in an ordered fashion encompassing additional brain regions with advancing disease stage [s9–s11]. 
Several mechanistic models have been put forward to explain the observation of gradual expansion of 
protein pathology in neurodegenerative disease. These include prion-like propagation [s12,s13], 
selective neuronal vulnerability via gene expression profiles [s14,s15] or via  activity-dependent 
metabolic demand [s16,s17].  
Advances have been made in the development of target-specific Positron-Emission-
Tomography (PET) tracers to visualize and quantify local molecular alterations (e.g., amyloid imaging, 
tau imaging, neurotransmitter imaging). Moreover, modern imaging techniques (e.g., resting state 
functional magnetic resonance imaging (rs-fMRI); diffusion tensor imaging (DTI), 
magnetoencephalography (MEG) have matured to obtain a holistic approach to the way, brain areas are 
functionally and structurally connected (“Connectomics”). These developments dovetail to provide a 
unique opportunity to examine how protein pathology in one location may gradually spread to other brain 
regions, or affect connectivity between them.  
In the following, we outline current concepts regarding the spatial and temporal determinants of 
accumulation of protein aggregates in human neurodegenerative disease and how the Connectomics 



































































neuropathological spreading. We close with our perspective on the challenges that need to be 
addressed to fully acknowledge the underlying complexity of brain networks and molecular variations 
associated with human neurodegenerative disease.  
 
1.1 Theories of Spreading 
Prion-like Propagation:  
The term “prion-like” propagation alludes to the observation that in prion disease, such as Creutzfeld-
Jakob disease, proteinaceous infectious particles (prions) increased with infectious activity and 
generated the formation of a conformer that can bind and convert other prion protein molecules into 
aberrant oligomers and insoluble aggregates [s18,s19]. This concept has been adopted to other 
disease-related proteins where the formation of fibrillar or oligomeric species initiates or ‘seeds’ the 
assimilation of non-pathological proteins into similar structural configurations. The resulting seeding 
process facilitates the aggregation of conformationally changed proteins that spread to interconnected 
neurons and adjacent glia cells [s20]. The pathological spread hypothesis is supplemented by the 
hypothesis that structural connectivity and synaptic activity among neurons direct the spread of 
pathology between cells and between regions. Where pathogenic oligomers or aggregates physically 
move from one neuron to another, and therefore spread into connected brain regions, it is referred to as 
non-cell-autonomy [s21].  
Selective vulnerability via gene expression profiles:   
The distinct concept of selective vulnerability posits that some neurons are intrinsically more vulnerable 
to a pathological process associated with the disease than others. This vulnerability may be explained 
by gene expression profiles of neurons that are more prone to protein accumulation and in turn more 
likely to become dysfunctional earlier in the disease process than other neuron assemblies [14,15]. For 
example in vitro experiments of human motor neurons identified different gene expression profiles in 
neurons resistant to amyotrophic lateral sclerosis (ALS) such as oculomotor neurons, compared to spinal 
motor neurons vulnerable to ALS [s22]. Further, within the dopaminergic system, neuronal phenotypes 
could be identified that are characterized by coordinated gene expression with distinct functional and 



































































(PD) [s23]. Together, this hypothesis centers on a cell-autonomous mechanism for the progression of 
pathology in neurodegenerative disease. Cell-autonomy often refers to the greater susceptibility of some 
neurons to adverse conditions, but it also includes the ability to amplify pathogenic protein species faster: 
amplification of toxic oligomeric or aggregated species is distinguished from their spread. Disease 
progression may be enhanced by both external stress and emergence of protein aggregates in more 
vulnerable neurons, and the transfer of protein aggregates by non-cell-autonomous mechanisms.  
Selective vulnerability via Activity-dependence:   
It has been proposed that highly active regions are more vulnerable to neurodegeneration. There are at 
least two mechanisms that may contribute to this observation.  The first is that neuronal activity can 
enhance the propagation of pathogenic proteins from cell to cell [s24] implying that highly active, and 
well connected, neurons are more likely to receive or transmit the pathology. Second, highly active cells 
may be more vulnerable to metabolic or other cellular stress, fostering the accumulation and misfolding 
of proteins [s16]. Cellular stress can arise by high physiological levels of excitation or disturbances of 
cellular homeostasis through inflammatory reactions, oxidative stress or shifting calcium demands [s14]. 
Computational modeling approaches in Alzheimer’s Disease (AD) have shown that highly connected 
brain regions (i.e., ‘hubs’) suffer from activity dependent degeneration, suggesting that the maintenance 
of excessive neuronal activity renders cortical hub regions to be more vulnerable for pathological disease 
development [s17]. Although this proposal focuses on environmentally-induced cellular stress, it 
acknowledges the contribution of “intrinsic stressors” (e.g., genetic background or advancing age) [s16]. 
Activity-dependent stress, and activity-dependent spread, call for new tools to examine the relationships 
between molecular substrates of disease, brain activity and brain connectivity.  
The advancement of functional and structural MRI and electrophysiological measures of synaptic activity 
such as MEG has characterized the brain’s network structure that appears to employ orchestrated 
processes underlying human cognitive function [s25]. Understanding the complexity with which these 
dynamic processes among brain networks interact and produce cognitive function is a field of its own 
and the interested reader is referred to excellent reviews on this topic [s26,s27]. Importantly, 



































































in human neurodegenerative disease relates to the brain’s intrinsic network architecture and which of 
the aforementioned proposals of protein accumulation may best describe disease progression. 
1.2 Measuring Pathology 
PET imaging allows the in vivo characterization of different molecular properties in the central 
nervous system, such as neuroinflammation, protein aggregates, regional glucose metabolism, synaptic 
density and neurotransmitter release. Each of these show different aspects of pathology in 
neurodegenerative disease. Imaging cerebral glucose metabolism using FDG-PET is a well-established 
method to examine the extent and regional pattern of neuronal dysfunction. It is in widespread clinical 
and research use for imaging neurodegeneration, with information about location and severity of the 
disease [28–30], but it does not provide etiological information about the molecular mechanisms 
underlying the neuronal dysfunction.  
Quantification of regional amyloid and tau burden in vivo has been reliant on PET imaging. 
Through the development of a novel class of PET tracers, targeting beta-amyloid (e.g., [C11]-PIB, [18F]-
Florbetapir, [18F]-Florbetaben, [18F]-Flutemetamol), the visualization and quantification of beta-amyloid 
plaques is now possible and used in large-scale studies, clinical trials, and even routinely implemented 
in clinical practice [28,31]. PET tracers targeting tau, although not yet fully validated, have already 
highlighted their potential in unraveling disease mechanisms and their progression, contribution to 
differential diagnosis and the establishment of a link between neuropathology and resulting clinical 
symptoms [6,32,33]. While first-generation tau tracers such as [18F]-AV1451, [18F]-THK5317, [18F]-
THK-5351, and [C11]-PBB3 expressed varying levels of off-target binding to midbrain regions, basal 
ganglia, choroid plexus and neuromelanin, second generation tau-PET tracers such as [18F]-PI2620, 
[18F]-MK-6240 or [18F]-RO9484 are hoped to overcome some of this off-target binding [s34].   
Neurodegeneration has also been associated with inflammation and loss of synapses. A 
comprehensive discussion on the development of new inflammation biomarkers and their contribution to 
neurodegeneration is provided by Rodriguez-Vietez et al., (2019) in this special section.  
To assess impaired nigrostriatal dopaminergic nerve terminals, a characteristic feature of early 
idiopathic PD, PET/SPECT markers of presynaptic dopamine transporters (e.g., [123I]FP-CIT) have been 



































































sensitivity seems to fade once loss exceeds 50 % [s35], thereby rendering this marker most sensitive to 
early phases of the disease. Another approach to assess dopaminergic function is using 18F-DOPA, 
which can estimate the dopamine turnover [s36] and has also been shown to track disease progression. 
Vesicular monoamine transporter 2 (VMAT2), a protein responsible for transporting monoamine 
neurotransmitters (dopamine, norepinephrine, serotonin) into synaptic vesicles for subsequent storage 
and release have been implicated in a variety of neurodegenerative disorders, including Parkinson’s and 
Huntington’s diseases [s37,s38].    
Finally, the loss of cholinergic cells in the basal forebrain has shown to be a contributor to early 
memory impairments in AD [39] and was associated with global build-up of cortical amyloid deposition 
during the preclinical phase [40]. Measuring cortical acetylcholinesterase enzyme activity using 11C-N-
methyl-4-piperidyl acetate (MP4A) PET imaging allows the evaluation of cholinergic neurotransmitter 
input via examining the regional cortical activity of acetylcholinesterase enzymes [41]. Others have 
employed an α4β2 nicotinic acetylcholine receptors (α4β2-nAChRs) specific radioligand (-)-18F-
Flubatine and observed significant relationships of cholinergic deficiency and impairment in measures 
of episodic memory and executive function [42].   
 
1.3 Measuring Connectomics  
Connectomics refers to the organizational principle of the brain as a host of distinct neuronal 
networks. Brain networks can be characterized via functional or structural properties depending on the 
imaging modality utilized to investigate brain networks.   
Electrophysiological measures of brain networks assess neuronal activity from surface sensors 
(EEG or MEG) with high temporal resolution and bandwidths typically of 1-100 Hz. Frequency-dependent 
correlations among sensors or electrodes of generalized synchronization have shown to reveal 
consistent dynamics and properties of brain networks [s43,s44]. These metrics can be used to identify 
more precise temporal dynamics of network connectivity [45], but measuring functional connectivity 
beyond the brain surface is restricted. This limitation is resolved by the application of functional 
connectivity information from resting-state functional MRI (rs-fMRI), which capitalizes on the statistical 



































































that may be derived from an anatomical atlas [s46] or randomly seeded) and the time-series of the blood 
oxygen level-dependent (BOLD) signal across the resting-state fMRI scan is extracted from each unit. 
Methods of analysis typically focus on co-variance patterns that elicit brain networks. The resulting brain 
networks are highly reproducible, and reveal organizational principles of the human brain [e.g., s26,47].  
Mapping the structural relationship between brain regions using diffusion imaging and 
tractography exploits water diffusion properties of fiber bundles anatomically connecting brain regions 
and allow the projection of cortico-cortical pathways [s48]. As this technique derives indices associated 
with the integrity of white matter microstructure it is referred to as ‘structural connectivity’ [s49,s50]. 
A novel approach to assess specific features of brain architecture is the identification of common 
regional gene expression profiles [s51]. Regional gene expression profiles reflect the molecular 
properties underlying specific brain tissue characteristics and allow the examination of spatially distinct 
patterns on a molecular level [s52,53]. 
1.4 Multimodal Imaging Studies on Connectomics and Molecular 
Pathology: 
The advancement of target-specific PET tracers to assess the molecular pathology in 
combination with functional and structural neuroimaging tools, offers the opportunity to test the different 
hypotheses underlying the development and the progression of pathology in human neurodegenerative 
diseases. With the advent of tracers to target beta-amyloid pathology [s54,s55] in combination with 
resting-state functional imaging it was possible to demonstrate that regions maxima of beta-amyloid 
deposition in AD patients are found predominantly in regions of the default mode network  [s56, s57, 58]. 
Further evidence suggested that disease specific atrophy pattern corresponded with functionally 
connected regions which promoted the concept of the network degeneration hypothesis [s59,s60]. This 
hypothesis summarizes evidence that different types of neurodegenerative pathologies apparently target 
specific neuronal functional networks [61–63].  In addition to studies underscoring the spatial 
correspondence between patterns of neurodegeneration (i.e., atrophy, metabolism) and functional brain 
networks, studies have shown that these functional brain networks undergo alterations in the face of 
disease or neuropathology [64]. For example, functional connectivity within the default mode network is 



































































extraneuronally and is ubiquitously distributed across the brain in advanced disease stage in AD, its 
direct relationship to network dysfunction and disease severity is less apparent  [s67]. The recent 
development of in vivo PET tracers to examine (intraneuronal) tau-pathology, thought to be more closely 
linked to neuronal injury and clinical symptoms, may close this gap [s6].  
Measuring retention of [18F]-AV1451 as a proxy of underlying tau pathology in amnestic AD 
dementia patients (N=22), and identifying regions that independently constitute networks of tau burden, 
Hoenig et al. (2018) utilized seeds of the highest uptake in each tau network to map where in the brain 
this region is functionally connected to. These tau-seed informed functional connectivity maps match the 
topology of known functional connectivity networks such as the ventral default mode network and the 
language network (see Figure 1.1). These functional networks of tau burden have been replicated in a 
larger group of patients spanning the entire spectrum of AD (N=218) [68] and support the hypothesis 
that the co-occurrence of tau accumulation in spatially distinct regions may be linked to their functional 
connections [47].   
Further evidence on the direct relationship between measures of functional connectivity and tau 
pathology in AD showed that densely interconnected brain regions (i.e., graph theoretical measures of 
weighted degree) accrue more tau pathology suggesting that higher connectivity renders regions to be 
more susceptive to tau deposition [69]. In a combined [18F]-AV1451-PET and resting state fMRI- study 
in addition to [18F]-AV45-PET study, Franzmeier and colleagues (2018) showed that higher resting-state 
functional connectivity between regions was associated with higher covariance in tau-PET binding in 
corresponding pairs of brain regions (see Figure 1.2). These results suggested a spatial similarity 
between the inter-regional connectivity and the sharing of tau between regions. Importantly, hotspots of 
tau accumulation such as the inferior temporal lobe, were associated with higher tau-PET uptake in 
functionally closely connected regions, suggesting that the level of tau deposition in a brain region varies 
as a function of its level of functional connectivity to a tau hot-spot. Interestingly, the relationship of 
similarity of tau levels and strength of functional connectivity was observed in cognitively normal older 
adults (N=82), in patients with MCI and AD (N=23) and in patients with vascular cognitive impairment 
(N=36), regardless of amyloid-status [70], suggesting that association between functional connectivity 



































































studies are of cross-sectional nature and longitudinal study approaches are needed to evaluate the 
progression of tau spreading via functional connectivity over time. Nevertheless, they are accumulatively 
suggesting a non-homogenous progression of tau pathology across independent brain networks that is 
closely related to functional connections between coherent brain regions.   
Congruent evidence from the temporal dimension of brain network dynamics was recently 
provided by Kocagoncu et al. (2019), who used a combination of MEG and [18F]-AV1451-PET in a group 
of AD patients (N=12). They reported that low frequencies (i.e., delta and theta band) oscillations of 
cortical nodes in neural networks are associated with increased tau burden. Detailed examination of 
these cortical nodes showed a reduction of the functional influence of nodes in the parieto-occipital 
network with elevated tau pathology, whereas frontal-temporal networks increased their influence on 
other regions with increasing tau pathology [45]. Overall, these results point to the idea that frequency-
dependent synchronous neuronal connectivity in brain regions relates to increased tau pathology. 
Figure 1 1) Overlap of Tau Networks and known functional Networks in Alzheimer’s Disease. Tau pathology networks 
correspond with functional connectivity networks quantified with a dice-coefficient of d=.57, d=.56 (adapted from 
Hönig et al.,). 2) Regions with high functional connectivity show covarying tau levels across normal aging, Alzheimer’s 



































































However, they also suggest a regional dissociation of up- and down-regulation of brain network 
connectivity in the face of tau pathology (see Figure 2). This pattern of up-regulation of functional network 
dynamics in frontal regions of the brain could be interpreted as a compensatory response of the brain to 
counteract the toxic effect of tau pathology. Corresponding with such an interpretation are data from 
Neitzel and coworkers (2019), who demonstrated that higher resting-state fMRI assessed hub 
connectivity in the left frontal cortex of the cognitive control network attenuates the adverse effect of 
higher entorhinal tau levels on episodic memory performance in both cognitively normal adults and 
patients in the prodromal phase of AD (N=125). This study provides evidence on how modulation of 
functional connectivity can mitigate deleterious effects of medial temporal tau pathology on the 
behavioral hallmarks of AD[71].  
Studies focusing on structural connectivity and its relationship to beta-amyloid pathology have 
shown that in individuals in the preclinical phase of AD, amyloid pathology is not sufficient to impair 
structural network connectivity [s72], and that cognitive decline over time is related to global 
characteristics of reduced diffusion in white matter tracts, but independently of beta-amyloid status [73]. 
In contrast, measures of tau pathology, and not beta-amyloid pathology, were related to reduced 
regional diffusion in temporal white matter tracts in a mixed sample of cognitively normal older adults 
and cognitively impaired individuals (N=69) [74]. Others have shown that in a group of cognitively normal 
older adults (N=256) the synergistic effect of increased beta-amyloid pathology and decreased 
microstructural integrity of the hippocampal cingulum bundle predicted increased tau deposition in the 
posterior cingulate cortex, as the major cortical output area of the hippocampus, and that this was also 
related to progressive memory decline in this group [75]. This line of evidence suggests that beta-
amyloid pathology exacerbates the spreading of tau accumulation from subcortical to cortical regions 
via white matter tracts connecting these regions. However, it has yet to be determined how structural 
connectivity across brain networks contributes to the widespread accumulation of tau pathology in 



































































Together, the existing evidence on assessing functional connectivity and molecular imaging 
across the spectrum of AD advances our understanding on the potential mechanisms of how AD 
pathology evolves in various brain regions. In the context of the theories of protein propagation, many of 
these data support the idea of non-cell-autonomous mechanisms, where connectivity among brain 
regions may direct the progression of AD pathology. It is important to note however, that these studies 
have not specifically assessed how measures of selective regional vulnerability would influence 
progression of AD pathology, therefore a conclusive statement on favoring a theoretical spreading 
proposal over another would be premature at this point. Another interesting hypothesis suggests that 
mislocalized/missorted tau proteins into the somatodendritic compartments of the neuronal cell at earlier 
stages of pathology [76] and may promote primarily disconnection between cell, which lead to tau 
pathology where such disconnection emerges.  
Figure 2 . 3) Correlations between network measures and tau deposition. Plots display correlations of participation 
coefficient (functional involvement in multiple modules) and eigenvector centrality (functional influence) with the 
local Tau burden across functional lobes in the delta and theta bands. All - whole brain; Fro - frontal; Lim - limbic; 



































































Further, the presented studies are broadly limited to the AD spectrum, and it remains an open 
question if functional connectivity plays an equally important role in the spreading of pathology in other 
human neurodegenerative disease forms, such as PD. Quantifying alpha-synuclein in PD patients in vivo 
has been limited by the reduced specificity of the available PET tracers (e.g, [123I]-SIL23) to selectively 
bind to alpha-synuclein [s77]. However, other molecular markers, such as [18F]‐fluoropropyl‐b‐CIT or 
[18F]-DOPA assessing the integrity of the dopaminergic system are available.  [18F]-DOPA has been 
recently combined with resting-state functional connectivity to examine the relationship of striatal 
dopamine synthesis and functional connectivity and how it relates to impulsive-compulsive behaviors in 
PD [78]. Hammes, Theis et al., (2019) observed that functional connectivity between the nucleus 
accumbens and the rostral anterior-cingulate was reduced in PD, and so was the dopamine synthesis 
capacity in the nucleus accumbens. Importantly, both measures were associated with the severity of 
impulsive-compulsive behaviors in the PD cohort (N=80), potentially representing the neurobiological 
constituents for the development of impulsive-compulsive behaviors in PD [79]. Moreover, multimodal 
imaging approaches in non-demented PD patients (N=50) revealed a reduction of the structural integrity 
of the cholinergic input from the basal forebrain to subcortical and cortical target areas. Importantly, this 
loss of structural integrity was paralleled by a reduction of functional connectivity between regions of the 
basal forebrain and bilateral hippocampus, middle and inferior frontal regions, thalamus and fusiform 
gyrus. Both reductions of connectivity and cholinergic input were associated with decreased cognitive 
function [80].  “Connectomics” as a measure of functional network integrity has been shown to be a 
sensitive parameter to capture individual differences among diverse PD populations [81]. For example, 
decreased global and network-specific connectivity appears to be characteristic of idiopathic PD 
(N=82), but only reductions in sensorimotor networks were associated with individual differences such 
as motor severity and dysexecutive deficits [82].  Further, connectivity alterations in the default mode 
network, executive networks and salience networks in drug-naïve PD patients (N=30) was a marker for 
the subsequent development of impulse control disorders after three years [83]. Intriguing evidence was 
recently provided showing that effective deep brain stimulation of the subthalamic nucleus alters the 
connectivity profiles of various networks, which in turn predicted clinical improvement [84]. Together 
these data emphasize that network connectivity can predict the phenotypical variation in PD and which 



































































A different line of research was recently developed by characterizing regional vulnerability to AD 
pathology in relation to the transcriptional architecture of the human brain as revealed by brain-wide 
regional gene expression profiling in neurotypical controls [53]. In a hypothesis-driven analysis focusing 
on the genes coding for the amyloid precursor (APP) and tau proteins (MAPT), Grothe et al., (2018) 
demonstrated that the regional severity of amyloid deposition in AD as measured by [18F]-AV45-PET, 
but not neurodegeneration on structural MRI, was positively correlated with regional expression levels of 
APP, whereas opposite associations were observed for MAPT (see Figure 3). Further, in a follow-up 
study the researchers showed that regional MAPT expression levels also predicted in-vivo trajectories of 
spreading tau pathology in the aging brain as measured by longitudinal acquisitions of tau-sensitive 
[18F]-AV1451-PET in cognitively normal older individuals (N=88) [85]. Together, the studies collectively 
suggest that the regional vulnerability to AD pathology in the human brain may at least be partly 
determined by specific systemic mechanisms associated with the molecular-functional properties of the 
affected neural systems, and that these properties largely differ for amyloid accumulation versus 
neurofibrillary degeneration [53].  
Similarly, regional expression profiles of the MAPT and SNCA (the gene encoding alpha-
synuclein) genes have also been linked to the specific pattern of functional connectivity disruptions 
Figure 4.. Regional expression levels of APP and MAPT genes (x-axes) correlate differentially with the regional severities of 
amyloid deposition (top) and neurodegeneration (bottom) in AD patients as compared to healthy controls (y-axes). Each point 
corresponds to one of 34 different cortical areas; r indicates Spearman correlation across these areas. Adopted from Grothe 



































































underlying cognitive impairments in PD (N=30) and progressive supranuclear palsy (PSP) (N=56) 
recently [86]. Whereas reduction in global connection strength was associated with MAPT gene 
expression, expression of SNCA was not. Further, connectivity reduction tracked cognitive but not 
clinical deficits, underscoring the possible independent contributions of regional vulnerability and 
network integrity towards phenotypical variation in PD. Another study found that the predominantly motor-
related atrophy pattern expressed by a cohort of non-demented de novo PD patients enrolled in the 
Parkinson’s Progression Markers Initiative (PPMI; N=149) was best predicted by regional expression 
levels of several genes implicated in trans-synaptic alpha-synuclein transfer [87]. Most interestingly, in 
another study on an overlapping sample of PD patients from the PPMI, the degree of regional atrophy 
correlated with the degree of functional and structural connectivity to a presumed disease epicenter in 
the substantia nigra, thus supporting a trans-neuronal spread model of atrophy progression in PD [88].  
In combination, these findings highlight that cell-autonomous and non-cell-autonomous 
processes need not be mutually exclusive but may interact in determining the complex temporo-spatial 
progression patterns observed in neurodegenerative disease. 
 
1.5 Summary and Outlook  
Our understanding of human neurodegenerative disease was previously limited to clinical data 
and inferences about the underlying pathology based on histopathological confirmation only. The 
development of complex neuroimaging tools and the advancement of target-specific PET tracers opens 
the opportunity to improve our understanding of the in vivo characteristics, dynamics, and principles of 
the progression of pathology in human neurodegenerative disease. Overall, the evidence underscores 
the utility of the Connectomics approach to identify the underlying principles of the distinct temporo-
spatial patterns characterizing pathological protein accumulation in neurodegenerative disease, and 
suggests that the connections between brain regions (functional or structural) may significantly 
contribute to the propagation of pathology. Although the causal nature of this spatial correspondence is 
poorly understood, data presented here suggests that susceptibility factors such as gene expression 
profiles may partly relate to the manifestation of pathology and neurodegeneration in distinct brain 



































































pathology accumulation and neurodegeneration, they do not fully account for the observed patterns of 
protein aggregation or neurodegeneration observed in AD and other neurodegenerative diseases.   
It is important to note that the currently existing in vivo neuroimaging tools do not have the spatial 
resolution to investigate cell-to-cell propagation of pathology. However integrative approaches on 
Connectomics, neurogenetics, and multimodal imaging (e.g., simultaneously with PET/MR) may 
methodologically be the most appropriate tools to capture the complex biological and functional aspects 
of the human brain itself, an advantage that cannot be easily translated from in vitro experiments. 
Although distinct histopathological hallmarks characterize different phenotypes of human 
neurodegenerative disease the occurrence of co-pathologies is increasingly recognized. For example, 
APOE ε4-carriers showed significantly more TDP-43 pathology, which was independent of AD  diagnosis 
or Lewy-body pathology and related to cognitive decline in a demented population [89]. Moreover, 
significant TDP-43 pathology was detected in half of the investigated sample of demented patients 
(N=1044), suggesting that multiple neuropathologies are the rule rather than the exception in late-onset 
dementia. The manifestation of multiple neuropathologies in human neurodegenerative disease may be 
particularly challenging when identifying the right target for disease modifying interventions. In the future, 
advances in the development of target-specific tracers of such co-pathologies (i.e., TDP-43, or alpha-
synuclein) may ultimately complete the picture on the emergence and interactions of in vivo co-
pathologies.    
Together the existing data provides evidence for both theoretical conceptions of non-cell-
autonomous and cell-autonomous mechanisms underlying aggregation of pathology. To this end, we 
propose a synergistic model (see Figure 5) that combines cell-autonomous (Figure 5.1) and non-cell-
autonomous (Figure 5.2) accounts of spreading as a triad of vulnerability. This triad includes the type of 
misfolded protein strains, local cell features and the Connectome that in synergistic combination produce 
relatively prototypical temporo-spatial patterns of neuronal dysfunction and cell loss, thereby potentially 






































































To test our proposed model, the paralleled investigation of molecular imaging of protein 
accumulation, structural and functional connectivity, gene expression profiling, and the characterization 
of activity-dependence of brain regions (see Figure 6) is needed. Such an approach allows the 
quantification of the factors contributing to selective vulnerability and in turn enables us to investigate its 
contribution to the pattern of neuronal dysfunction (see Figure 6).  
In summary, the combination of Connectomics and molecular imaging has revealed important 
insights into the development and progression of human neurodegenerative disease and the 
development of phenotypical variation. As we move forward, we recognize that the current hypothesis 
 
Figure 5. Triad of Vulnerability:  A unification of the cell-autonomous and cell-non-autonomous accounts of protein 
aggregation, via a triad-interaction of protein strain, cell feature and Connectome may instigate the neural vulnerability that 




































































on pathological spreading and regional vulnerability may have to be investigated in concert to advance 
our understanding on disease progression. Although several limitations may hinder us at the moment to 
achieve a complete picture on the causes of development and progression of human neurodegenerative 
disease, the insights from clinical in-vivo neuroimaging research achieved thus far have altered our 
conception of target-specific intervention windows, primary and secondary outcome measures, and 




Figure 6 Example of how the synergistic triad of vulnerability may translate into the clinical phenotypes of  AD. 
Investigations of protein accumulation and examination of the critical contribution of the connectome and cell feature such 
as metabolic demand or gene expression profiles  may lead to the observed spatial pattern of neuronal dysfunction that in 
turn produces distinct clinical phenotype in AD. AD = Alzheimer’s Disease, bvAD = behavioral variant of AD, lvPPA = 






































































Compliance with Ethical Standards:  
Funding: The Molecular Imaging of Neurodegeneration Cologne (MINC) Symposium was partly funded 
by the Deutsche Forschungsgemeinschaft (DFG) awarded to Dr. Thilo van Eimeren (EI 892/5-1). The 
Deutsche Forschungsgemeinschaft (DFG) also awarded funding to Dr. Alexander Drzezga (DR 
442/91).   
Conflict of Interest: The authors declare no conflict of interest in relation to this article.  
Ethic Approval:  All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 1964 
Helsinki declaration and its later amendments or comparable ethical standards. 
 
Bibliography:  
6. Bischof GN, Endepols H, van Eimeren T, Drzezga A. Tau-imaging in neurodegeneration. Methods. 
2017;130:114–23.  
28. Hammes J, Bischof GN, Drzezga A. Molecular imaging in early diagnosis, differential diagnosis 
and follow-up of patients with neurodegenerative diseases. Clin Transl Imaging. 2017;5:465–71.  
29. Teipel S, Drzezga A, Grothe MJ, Barthel H, Chételat G, Schuff N, et al. Multimodal imaging in 
Alzheimer’s disease: validity and usefulness for early detection. The Lancet Neurology. 
2015;14:1037–53.  
30. Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Van Eimeren T, et al. Molecular 
imaging to track Parkinson’s disease and atypical parkinsonisms: New imaging frontiers. Mov Disord. 
2017;32:181–92.  
31. Barthel H, Sabri O. Clinical Use and Utility of Amyloid Imaging. J Nucl Med. 2017;58:1711–7.  
32. Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau PET 
imaging: present and future directions. Molecular Neurodegeneration [Internet]. 2017 [cited 2017 Mar 
31];12. Available from: 
http://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-017-0162-3 



































































18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear 
palsy. Brain. 2017;  
39. Grothe M, Heinsen H, Teipel SJ. Atrophy of the cholinergic Basal forebrain over the adult age 
range and in early stages of Alzheimer’s disease. Biol Psychiatry. 2012;71:805–13.  
40. Grothe MJ, Ewers M, Krause B, Heinsen H, Teipel SJ, Alzheimer’s Disease Neuroimaging 
Initiative. Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. 
Alzheimers Dement. 2014;10:S344-353.  
41. Richter N, Beckers N, Onur OA, Dietlein M, Tittgemeyer M, Kracht L, et al. Effect of cholinergic 
treatment depends on cholinergic integrity in early Alzheimer’s disease. Brain. 2018;141:903–15.  
42. Sabri O, Meyer PM, Gräf S, Hesse S, Wilke S, Becker G-A, et al. Cognitive correlates of α4β2 
nicotinic acetylcholine receptors in mild Alzheimer’s dementia. Brain. 2018;141:1840–54.  
45. Kocagoncu E, Quinn A, Firouzian A, Cooper E, Greve A, Gunn R, et al. Tau pathology in early 
Alzheimer’s disease disrupts selective neurophysiological networks dynamics. bioRxiv. 2019;524355.  
47. Hoenig MC, Bischof GN, Seemiller J, Hammes J, Kukolja J, Onur ÖA, et al. Networks of tau 
distribution in Alzheimer’s disease. Brain. 2018;  
53. Grothe MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, Schöll M, Hansson O, et al. 
Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology. Brain. 
2018;141:2755–71.  
58. Grothe MJ, Teipel SJ, Alzheimer’s Disease Neuroimaging Initiative. Spatial patterns of atrophy, 
hypometabolism, and amyloid deposition in Alzheimer’s disease correspond to dissociable functional 
brain networks. Hum Brain Mapp. 2016;37:35–53.  
61. Drzezga A. The Network Degeneration Hypothesis: Spread of Neurodegenerative Patterns Along 
Neuronal Brain Networks. J Nucl Med. 2018;59:1645–8.  
62. Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between 
atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67:317–24.  
63. Myers N, Pasquini L, Göttler J, Grimmer T, Koch K, Ortner M, et al. Within-patient 
correspondence of amyloid-β and intrinsic network connectivity in Alzheimer’s disease. Brain. 
2014;137:2052–64.  
64. Drzezga A, Becker JA, Van Dijk KRA, Sreenivasan A, Talukdar T, Sullivan C, et al. Neuronal 
dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid 
burden. Brain. 2011;134:1635–46.  
65. Koch K, Myers NE, Göttler J, Pasquini L, Grimmer T, Förster S, et al. Disrupted Intrinsic 
Networks Link Amyloid-β Pathology and Impaired Cognition in Prodromal Alzheimer’s Disease. 
Cereb Cortex. 2015;25:4678–88.  
68. Jones DT, Graff-Radford J, Lowe VJ, Wiste HJ, Gunter JL, Senjem ML, et al. Tau, amyloid, and 
cascading network failure across the Alzheimer’s disease spectrum. Cortex. 2017;97:143–59.  
69. Cope TE, Rittman T, Borchert RJ, Jones PS, Vatansever D, Allinson K, et al. Tau burden and the 




































































70. Franzmeier N, Rubinski A, Neitzel J, Kim Y, Damm A, Na DL, et al. Functional connectivity 
associated with tau levels in ageing, Alzheimer’s, and small vessel disease. Brain. 2019;  
71. Neitzel J, Franzmeier N, Rubinski A, Ewers M. Left frontal connectivity attenuates the adverse 
effect of entorhinal tau pathology on memory. Neurology. 2019;in press.  
73. Rabin JS, Perea RD, Buckley RF, Neal TE, Buckner RL, Johnson KA, et al. Global White Matter 
Diffusion Characteristics Predict Longitudinal Cognitive Change Independently of Amyloid Status in 
Clinically Normal Older Adults. Cereb Cortex. 2019;29:1251–62.  
74. Strain JF, Smith RX, Beaumont H, Roe CM, Gordon BA, Mishra S, et al. Loss of white matter 
integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology. 2018;91:e313–8.  
75. Jacobs HIL, Hedden T, Schultz AP, Sepulcre J, Perea RD, Amariglio RE, et al. Structural tract 
alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci. 
2018;21:424–31.  
76. Zempel H, Mandelkow E. Lost after translation: missorting of Tau protein and consequences for 
Alzheimer disease. Trends in Neurosciences. 2014;37:721–32.  
78. Hammes J, Theis H, Giehl K, Hoenig MC, Greuel A, Tittgemeyer M, et al. Dopamine metabolism 
of the nucleus accumbens and fronto-striatal connectivity modulate impulse control. Brain. 
2019;142:733–43.  
79. Strafella AP. Mesolimbic dopamine and anterior cingulate cortex connectivity changes lead to 
impulsive behaviour in Parkinson’s disease. Brain. 2019;142:496–8.  
80. Gargouri F, Gallea C, Mongin M, Pyatigorskaya N, Valabregue R, Ewenczyk C, et al. Multimodal 
magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in 
Parkinson’s disease. Mov Disord. 2019;34:516–25.  
81. Tahmasian M, Eickhoff SB, Giehl K, Schwartz F, Herz DM, Drzezga A, et al. Resting-state 
functional reorganization in Parkinson’s disease: An activation likelihood estimation meta-analysis. 
Cortex. 2017;92:119–38.  
82. Lang S, Hanganu A, Gan LS, Kibreab M, Auclair-Ouellet N, Alrazi T, et al. Network basis of the 
dysexecutive and posterior cortical cognitive profiles in Parkinson’s disease. Mov Disord. 2019;  
83. Tessitore A, De Micco R, Giordano A, di Nardo F, Caiazzo G, Siciliano M, et al. Intrinsic brain 
connectivity predicts impulse control disorders in patients with Parkinson’s disease. Mov Disord. 
2017;32:1710–9.  
84. Horn A, Reich M, Vorwerk J, Li N, Wenzel G, Fang Q, et al. Connectivity Predicts deep brain 
stimulation outcome in Parkinson disease. Ann Neurol. 2017;82:67–78.  
85. Sepulcre J, Grothe MJ, d’Oleire Uquillas F, Ortiz-Terán L, Diez I, Yang H-S, et al. Neurogenetic 
contributions to amyloid beta and tau spreading in the human cortex. Nat Med. 2018;24:1910–8.  
86. Rittman T, Rubinov M, Vértes PE, Patel AX, Ginestet CE, Ghosh BCP, et al. Regional expression 
of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in 



































































87. Freeze B, Acosta D, Pandya S, Zhao Y, Raj A. Regional expression of genes mediating trans-
synaptic alpha-synuclein transfer predicts regional atrophy in Parkinson disease. Neuroimage Clin. 
2018;18:456–66.  
88. Zeighami Y, Ulla M, Iturria-Medina Y, Dadar M, Zhang Y, Larcher KM-H, et al. Network 
structure of brain atrophy in de novo Parkinson’s disease. Elife. 2015;4.  
89. Yang H-S, Yu L, White CC, Chibnik LB, Chhatwal JP, Sperling RA, et al. Evaluation of TDP-43 
proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based 
cohort study. Lancet Neurol. 2018;17:773–81.  
90. van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, et al. Neuroimaging 
biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging 
Biomarker Utility System. Alzheimers Dement (Amst). 2019;11:301–9.  
 


































































Click here to access/download;Figure;Figure1_2.png
Click here to access/download;Figure;Figure3.png
Click here to access/download;Figure;Figure4.png
Click here to access/download;Figure;Figure5_Bischof_EJNMMI.tif
Click here to access/download;Figure;Figure6_Bischof_EJNMMI.tif




Click here to access/download
Supplementary Material
EJNMMI_2019_Mincs_Proceedings_Bischof_Supplemen
taryII.docx
